A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)
- Conditions
- Myocardial Infarction
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1671
- Registration Number
- NCT00168792
- Locations
- ๐น๐ท
Boehringer Ingelheim Investigational Site, Izmir, Turkey
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)
- Conditions
- HypertensionDiabetic Nephropathies
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 860
- Registration Number
- NCT00168857
- Locations
- ๐ฒ๐ฝ
Fracc. Magallanes, Acapulco Guerrero, Mexico
๐บ๐ธVA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States
๐น๐ญPramongkutklao Hospital, Bangkok, Thailand
Rt-PA in the Treatment of Acute Ischemic Stroke
- Conditions
- Cerebrovascular Accident
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 821
- Registration Number
- NCT00153036
- Locations
- ๐ฆ๐น
135.312.43007 Boehringer Ingelheim Investigational Site, Innsbruck, Austria
๐ฆ๐น135.312.43004 Boehringer Ingelheim Investigational Site, Graz, Austria
๐ฆ๐น135.312.43006 Boehringer Ingelheim Investigational Site, Salzburg, Austria
Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 361
- Registration Number
- NCT00157248
- Locations
- ๐บ๐ธ
1160.42.10013 Boehringer Ingelheim Investigational Site, New Hyde Park, New York, United States
๐ณ๐ฑ1160.42.31008 Gelre Ziekenhuis, locatie Juliana, Apeldoorn, Netherlands
๐ฉ๐ฐ1160.42.45005 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark
Thrombolysis Using Tenecteplase (Metalyseยฎ) in Cardiac Arrest - The TROICA Trial
- Conditions
- Heart Arrest
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1050
- Registration Number
- NCT00157261
- Locations
- ๐ฆ๐น
Univ.-Klinik f. Notfallmedizin, Wien, Austria
๐ง๐ชAZ VUB, Bruxelles, Belgium
๐ง๐ชAZ Groeningen, Kortrijk, Belgium
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
- Conditions
- Stroke
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20332
- Registration Number
- NCT00153062
- Locations
- ๐บ๐ธ
9.159.1197 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
๐บ๐ธ9.159.1024 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
๐บ๐ธ9.159.1005 Boehringer Ingelheim Investigational Site, Fort Smith, Arkansas, United States
1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
- Conditions
- Diabetic NephropathiesHypertension
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 885
- Registration Number
- NCT00153023
- Locations
- ๐จ๐ฟ
District Hospital Tabor, Tabor, Czech Republic
๐ซ๐ทHopital A.Mignot, Le Chesnay, France
๐จ๐ฟUniversity Hospital Hradec Kralove, Hradec Kralove, Czech Republic
3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 583
- Registration Number
- NCT00153049
- Locations
- ๐ฏ๐ต
Boehringer Ingelheim Investigational Site, Taya-gun, Gunma, Japan
A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 224
- Registration Number
- NCT00152958
- Locations
- ๐ฉ๐ช
Clinpharm International GmbH & Co. KG, Berlin (Hellersdorf), Germany
๐ฉ๐ชemovis GmbH, Berlin, Germany
๐ฉ๐ชParacelsus-Elena-Klinik, Kassel, Germany
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type
- Conditions
- Alzheimer Disease
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 430
- Registration Number
- NCT00153010
- Locations
- ๐บ๐ธ
Margolin Brain Institute, Fresno, California, United States
๐บ๐ธSouthwest Institute for Clinical Research, Rancho Mirage, California, United States
๐บ๐ธNorth Michigan Neurology, Traverse City, Michigan, United States